董事会宣布截至本公告日期，已根据2022年受限制股份单位计划向2022年受限制股份单位计划的2名获选人士(2022年获选人士)授出29万份受限制股份单位(2022年奖励)，相当于29万股股份(2022年进一步授出)。其中，公司执行董事兼首席执行官杨大俊获授19万份受限制股份单位，相当于19万股股份;而公司首席医学官兼主要股东翟一帆获授10万份受限制股份单位，相当于10万股股份。Yasheng Medicine-B (06855) announced that as of the date of this announcement, the board of directors has granted restricted stock units in accordance with the 2018 restricted stock unit plan.
The board of directors announced that as of the date of this announcement, it has granted a total of 2.0594 million restricted stock units (2018 award) to 138 selected individuals under the 2018 restricted stock unit plan, equivalent to 2.0594 million shares of stock (further granted in 2018).
The board of directors announced that as of the date of this announcement, it has granted 1.1969 million restricted stock units (2021 award) to 439 selected individuals under the 2021 restricted stock unit plan, equivalent to 1.1969 million shares of stock (further granted in 2021).
The board of directors announced that as of the date of this announcement, it has granted 0.29 million restricted stock units (2022 award) to 2 selected individuals under the 2022 restricted stock unit plan, equivalent to 0.29 million shares of stock (further granted in 2022). Among them, Yang Dajun, the company's executive director and CEO, was granted 0.19 million restricted stock units, equivalent to 0.19 million shares of stock; while Dr. Zhai Yifan, the chief medical officer and major shareholder of the company, was granted 0.1 million restricted stock units, equivalent to 0.1 million shares of stock.
